As regards T2D and obesity treatment, there are currently approved GLP-1 RAs such as exenatide, liraglutide and lixisenatide which are resistant to the enzymatic cleavage of dipeptidyl peptidase-4 (DPP-4), thus accounting for an increased half-life in comparison to endogenous GLP-1, that have shown positive management of the disease (Aroda, 2018). The gene discussed is GLP1R; the disease is Obesity.